

## **ESP Advanced Training Centre for Haematopathology**

### **Cambridge University Hospitals NHS Foundation Trust/ Cambridge University**

**Name and address of centre:** Joint arrangement between the Haematopathology and Oncology Diagnostic Service, Level 3, Addenbrookes Hospital, Hills Road, Cambridge CB2 0QQ and the Division of Cellular and Molecular Pathology, Department of Pathology, Cambridge University, Level 3, Addenbrookes Hospital, Hills Road, Cambridge CB2 0QQ

#### **Chair of the centre:**

(1) Haematopathology and Oncology Diagnostic Service: Dr Mike Scott, Consultant Clinical Scientist, Cambridge University Hospitals NHS Foundation Trust

(2) Division of Cellular and Molecular Pathology, Department of Pathology, Cambridge University: Professor Nicholas Coleman

**Head of the medical haematopathology training programme:** Dr Elizabeth Soilleux, Honorary Consultant Pathologist, Haematopathology and Oncology Diagnostic Service/ University Lecturer <https://www.path.cam.ac.uk/directory/elizabeth-soilleux>

**Overview of the Centre:** Haematopathology is an expanding and increasingly complex subspeciality that crosses boundaries between histopathology and haematology. Haematopathology is regarded as one of the most challenging disciplines within histopathology because the modern diagnosis and treatment of haematological malignancies requires very significant understanding of the molecular basis of the conditions, as well as appreciation of morphology, immunohistochemistry and cytogenetics. Furthermore, it requires an integrated approach using all of these techniques in conjunction with diagnostic flow cytometry and bone marrow aspirate morphology, both of which have traditionally been reported by haematologists. This fellowship is aimed initially at senior histopathology and molecular pathology trainees, but may also be appropriate for senior haematology trainees to permit cross-speciality training.

[The Haematopathology and Oncology Diagnostic Service](#) (HODS) in Cambridge is a leading UK haematopathology service, serving a population of approximately 5 million people, and is the only UK centre providing the necessary fully integrated service incorporating haematopathology, cytomorphology, flow cytometry, cytogenetics and molecular diagnostics. We currently have a team including 4 histopathologists, 3 haematologists and 2 consultant clinical scientists in addition to 50 laboratory scientists. There is a strong ethos of training within the department, with the capacity and drive to provide high quality training to consultant level. There are also strong research links between HODS and the University of Cambridge Departments of Haematology, Histopathology and Molecular Pathology and the fellowship will provide opportunities for the individual to become involved in a research project during the post.

Adjacent to HODS is the Cellular and Molecular Division of Cambridge University's [Department of Pathology](#), in which there are a number of research groups involved in cutting edge lymphoma, molecular diagnostics and cancer research. Cambridge now hosts the largest [biomedical campus](#) in Europe. Many outstanding haematology research groups are thus present in adjacent institutions providing ideal opportunity for collaboration. Opportunities for industrial collaboration also abound with [Astra Zeneca](#)'s recent move to the [Cambridge Biomedical Campus](#) and an abundance of both start-ups and more established

biotechnology and information technology focussed companies on Cambridge's many science parks.

[Cambridge](#) is a small but vibrant city, with a very international feel, which is packed with things to see and do. It is particularly well-known for its architecture, heritage, world renowned university and its many museums. It has several theatres, including the ADC theatre, home of the [Cambridge Footlights](#), an organisation which has produced many famous actors and comedians. The centre of Cambridge along "[The Backs](#)" as the beautiful region along the river is known, has been likened by many to fairyland. There are few better feelings than relaxing in a [punt](#) on the river on a sunny day!

***Areas in which training can be offered:*** haematopathology, laboratory haematology and molecular diagnostics, with the additional option of becoming involved in collaborative research projects. Cambridge is an outstanding centre for translational biomedical sciences, particularly in haematology, pathology, molecular diagnostics and cancer biology, giving unrivalled opportunity for collaborative research.

***Number of positions offered for each year:*** Up to four per year in any combination of haematopathology, laboratory haematology and molecular diagnostics. The exact number of posts depends on available funding from the Giordano fellowship scheme.

***Expected duration of the training:*** 3 months, unless additional funding outwith the Giordano fellowship scheme can be arranged .

***Specific periods of the year when the visit may be realized:*** Any time.

***Teaching:*** Opportunities exist to contribute to the teaching of Cambridge university undergraduate students.

***Accommodation:*** Affordable accommodation can be found via several routes, including the hospital and university's accommodation services, as well as privately.

<https://www.accommodation.cam.ac.uk>

<https://www.sanctuary-addenbrookes.co.uk/>

***Contact address for requesting details by the applicant:*** Dr Elizabeth Soilleux, University Lecturer, Division of Cellular and Molecular Pathology, Lab Block Level 3, Box 231, Addenbrooke's Hospital, Cambridge CB2 0QQ E-mail: [ej17@cam.ac.uk](mailto:ej17@cam.ac.uk)  
<https://www.path.cam.ac.uk/directory/elizabeth-soilleux>

**2018**

Beck D, Thoms JAI, Palu C, Herold T, Shah A, Olivier J, Boelen L, Huang Y, Chacon D, Brown A, Babic M, Hahn C, Perugini M, Zhou X, Huntly BJ, Schwarzer A, Klusmann JH, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Bohlander SK, To LB, Scott HS, Lewis ID, D'Andrea RJ, Wong JWH, Pimanda JE. A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients. **Leukemia**. 2018 Feb;32(2):263-272. doi: 10.1038/leu.2017.210. Epub 2017 Jul 4. PubMed PMID: 28674423.

Booth CAG, Barkas N, Neo WH, Boukarabila H, Soilleux EJ, Giotopoulos G, Farnoud N, Giustacchini A, Ashley N, Carrelha J, Jamieson L, Atkinson D, Bouriez-Jones T, Prinjha RK, Milne TA, Teachey DT, Papaemmanuil E, Huntly BJP, Jacobsen SEW, Mead AJ. Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors. **Cancer Cell**. 2018 Feb 12;33(2):274-291.e8. doi: 10.1016/j.ccell.2018.01.006. PubMed PMID: 29438697.

Comoglio F, Park HJ, Schoenfelder S, Barozzi I, Bode D, Fraser P, Green AR. Thrombopoietin signaling to chromatin elicits rapid and pervasive epigenome remodeling within poised chromatin architectures. **Genome Res**. 2018 Feb 2. pii: gr.227272.117. doi: 10.1101/gr.227272.117. [Epub ahead of print] PubMed PMID: 29429976.

Dietrich S, Oleś M, Lu J, Sellner L, Anders S, Velten B, Wu B, Hüllelein J, da Silva Liberio M, Walther T, Wagner L, Rabe S, Ghidelli-Disse S, Bantscheff M, Oleś AK, Słabicki M, Mock A, Oakes CC, Wang S, Oppermann S, Lukas M, Kim V, Sill M, Benner A, Jauch A, Sutton LA, Young E, Rosenquist R, Liu X, Jethwa A, Lee KS, Lewis J, Putzker K, Lutz C, Rossi D, Mokhir A, Oellerich T, Zirlik K, Herling M, Nguyen-Khac F, Plass C, Andersson E, Mustjoki S, von Kalle C, Ho AD, Hensel M, Dürig J, Ringshausen I, Zapatka M, Huber W, Zenz T. Drug-perturbation-based stratification of blood cancer. **J Clin Invest**. 2018 Jan 2;128(1):427-445. doi:10.1172/JCI93801. Epub 2017 Dec 11. PubMed PMID: 29227286; PubMed Central PMCID: PMC5749541.

Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, Basheer F, Marando L, Di Lisio L, Dias JML, Yun H, Sasca D, Horton SJ, Vassiliou G, Frezza C, Huntly BJP. Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. **Blood**. 2018 Feb 20. pii: blood-2017-12-820035. doi: 10.1182/blood-2017-12-820035. [Epub ahead of print] PubMed PMID: 29463564.

Li J, Prins D, Park HJ, Grinfeld J, Gonzalez-Arias C, Loughran S, Dovey OM, Klampfl T, Bennett C, Hamilton TL, Pask DC, Sneade R, Williams M, Aungier J, Ghevaert C, Vassiliou GS, Kent DG, Green AR. Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. **Blood**. 2018 Feb 8;131(6):649-661. doi: 10.1182/blood-2017-09-806356. Epub 2017 Dec 27. PubMed PMID: 29282219.

Nice FL, Massie CE, Klampfl T, Green AR. Determination of complex subclonal structures of hematological malignancies by multiplexed genotyping of blood progenitor colonies. **Exp Hematol**. 2018 Jan;57:60-64.e1. doi: 10.1016/j.exphem.2017.09.011. Epub 2017 Oct 9. PubMed PMID: 29024710; PubMed Central PMCID: PMC5731633.

Pagano F, Comoglio F, Grinfeld J, Li J, Godfrey A, Baxter J, Silber Y, Green AR. MicroRNA-101 expression is associated with JAK2V617F activity and regulates JAK2/STAT5 signaling. **Leukemia**. 2018 Feb 27. doi: 10.1038/s41375-018-0053-9. [Epub ahead of print] PubMed PMID: 29483713.

Vrzalikova K, Ibrahim M, Vockerodt M, Perry T, Margielewska S, Lupino L, Nagy E, Soilleux E, Liebelt D, Hollows R, Last A, Reynolds G, Abdullah M, Curley H, Care M, Krappmann D, Tooze R, Allegood J, Spiegel S, Wei W, Woodman CBJ, Murray, PG. S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells. **Leukemia**. 2018 Jan;32(1):214-223. doi: 10.1038/leu.2017.275. Epub 2017 Sep 7. PubMed PMID: 28878352; PubMed Central PMCID: PMC5737877.

## 2017

Bashford-Rogers RJ, Palser AL, Hodgkinson C, Baxter J, Follows GA, Vassiliou GS, Kellam P. Dynamic variation of CD5 surface expression levels within individual chronic lymphocytic leukemia clones. **Exp Hematol**. 2017 Feb;46:31-37.e10. doi: 10.1016/j.exphem.2016.09.010. Epub 2016 Sep 28. PubMed PMID: 27693386; PubMed Central PMCID: PMC5261558.

Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. **J Clin Oncol**. 2017 Dec 10;35(35):3898-3905. doi:10.1200/JCO.2017.75.4648. Epub 2017 Oct 4. PubMed PMID: 28976790.

Du MQ. MALT lymphoma: Genetic abnormalities, immunological stimulation and molecular mechanism. **Best Pract Res Clin Haematol**. 2017 Mar - Jun;30(1-2):13-23. doi: 10.1016/j.beha.2016.09.002. Epub 2016 Nov 4. Review. PubMed PMID: 28288707.

Egger G, Turner SD. New avenues for targeted therapies and biomarkers in anaplastic large cell lymphoma. **Epigenomics**. 2017 Feb;9(2):97-100. doi: 10.2217/epi-2016-0159. Epub 2017 Jan 18. PubMed PMID: 28097892.

Gallipoli P, Huntly BJP. Novel epigenetic therapies in hematological malignancies: Current status and beyond. **Semin Cancer Biol**. 2017 Aug 4. pii: S1044-579X(17)30135-9. doi: 10.1016/j.semcancer.2017.07.005. [Epub ahead of print] Review. PubMed PMID: 28782607.

Grinfeld J, Nangalia J, Green AR. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. **Haematologica**. 2017

Jan;102(1):7-17. doi: 10.3324/haematol.2014.113845. Epub 2016 Dec 1. Review. PubMed PMID: 27909216; PubMed Central PMCID: PMC5210228.

Harrison CN, McMullin MF, Green AR, Mead AJ. Equivalence of BCSH and WHO diagnostic criteria for ET. **Leukemia**. 2017 Jul;31(7):1660. doi: 10.1038/leu.2017.119. Epub 2017 May 5. PubMed PMID: 28474678.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. **N Engl J Med**. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324. PubMed PMID: 28273028.

Horton SJ, Giotopoulos G, Yun H, Vohra S, Sheppard O, Bashford-Rogers R, Rashid M, Clipson A, Chan WI, Sasca D, Yiangou L, Osaki H, Basheer F, Gallipoli P, Burrows N, Erdem A, Sybirna A, Foerster S, Zhao W, Sustic T, Petrunkina Harrison A, Laurenti E, Okosun J, Hodson D, Wright P, Smith KG, Maxwell P, Fitzgibbon J, Du MQ, Adams DJ, Huntly BJP. Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. **Nat Cell Biol**. 2017 Sep;19(9):1093-1104. doi: 10.1038/ncb3597. Epub 2017 Aug 21. PubMed PMID: 28825697; PubMed Central PMCID: PMC5633079.

Johnson L, O'Donoghue JM, McLean N, Turton P, Khan AA, Turner SD, Lennard A, Collis N, Butterworth M, Gui G, Bristol J, Hurren J, Smith S, Grover K, Spyrou G, Krupa K, Azmy IA, Young IE, Staiano JJ, Khalil H, MacNeill FA. Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent. **Eur J Surg Oncol**. 2017 Aug;43(8):1393-1401. doi: 10.1016/j.ejso.2017.05.004. Epub 2017 May 18. PubMed PMID: 28596034.

Kazianka L, Drucker C, Skrabs C, Thomas W, Melchardt T, Struve S, Bergmann M, Staber PB, Porpaczy E, Einberger C, Heinz M, Hauswirth A, Raderer M, Pabinger I, Thalhammer R, Egle A, Wendtner CM, Follows G, Hoermann G, Quehenberger P, Jilma B, Jaeger U. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. **Leukemia**. 2017 May;31(5):1117-1122. doi: 10.1038/leu.2016.316. Epub 2016 Nov 2. PubMed PMID: 27909342; PubMed Central PMCID: PMC5338745.

Kent DG, Green AR. Order Matters: The Order of Somatic Mutations Influences Cancer Evolution. **Cold Spring Harb Perspect Med**. 2017 Apr 3;7(4). pii: a027060. doi: 10.1101/cshperspect.a027060. Review. PubMed PMID: 28096247; PubMed Central PMCID: PMC5378012.

Kirschner K, Chandra T, Kiselev V, Flores-Santa Cruz D, Macaulay IC, Park HJ, Li J, Kent DG, Kumar R, Pask DC, Hamilton TL, Hemberg M, Reik W, Green AR. Proliferation Drives Aging-Related Functional Decline in a Subpopulation of the Hematopoietic Stem Cell Compartment. **Cell Rep**. 2017 May 23;19(8):1503-1511. doi: 10.1016/j.celrep.2017.04.074. PubMed PMID: 28538171; PubMed Central PMCID: PMC5457484.

Kiselev VY, Kirschner K, Schaub MT, Andrews T, Yiu A, Chandra T, Natarajan KN, Reik W, Barahona M, Green AR, Hemberg M. SC3: consensus clustering of single-cell RNA-seq data. **Nat Methods**. 2017 May;14(5):483-486. doi: 10.1038/nmeth.4236. Epub 2017 Mar 27. PubMed PMID: 28346451; PubMed Central PMCID: PMC5410170.

Kollmann K, Warsch W, Gonzalez-Arias C, Nice FL, Avezov E, Milburn J, Li J, Dimitropoulou D, Biddie S, Wang M, Poynton E, Colzani M, Tijssen MR, Anand S, McDermott U, Huntly B, Green T. A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation. **Leukemia**. 2017 Apr;31(4):934-944. doi: 10.1038/leu.2016.280. Epub 2016 Oct 14. PubMed PMID: 27740635; PubMed Central PMCID: PMC5383931.

Loughran SJ, Comoglio F, Hamey FK, Giustacchini A, Errami Y, Earp E, Göttgens B, Jacobsen SEW, Mead AJ, Hendrich B, Green AR. Mbd3/NuRD controls lymphoid cell fate and inhibits tumorigenesis by repressing a B cell transcriptional program. **J Exp Med**. 2017 Oct 2;214(10):3085-3104. doi: 10.1084/jem.20161827. Epub 2017 Sep PubMed PMID: 28899870; PubMed Central PMCID: PMC5626393.

Mohr S, Doebele C, Comoglio F, Berg T, Beck J, Bohnenberger H, Alexe G, Corso J, Ströbel P, Wachter A, Beissbarth T, Schnütgen F, Cremer A, Haetscher N, Göllner S, Rouhi A, Palmqvist L, Rieger MA, Schroeder T, Bönig H, Müller-Tidow C, Kuchenbauer F, Schütz E, Green AR, Urlaub H, Stegmaier K, Humphries RK, Serve H, Oellerich T. Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. **Cancer Cell**. 2017 Apr 10;31(4):549-562.e11. doi: 10.1016/j.ccell.2017.03.001. PubMed PMID: 28399410; PubMed Central PMCID: PMC5389883.

Moody S, Escudero-Ibarz L, Wang M, Clipson A, Ochoa Ruiz E, Dunn-Walters D, Xue X, Zeng N, Robson A, Chuang SS, Cogliatti S, Liu H, Goodlad J, Ashton-Key M, Raderer M, Bi Y, Du MQ. Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma. **J Pathol**. 2017 Sep;243(1):3-8. doi: 10.1002/path.4933. Epub 2017 Aug 7. PubMed PMID: 28682481.

Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. **Hematology Am Soc Hematol Educ Program**. 2017 Dec 8;2017(1):470-479. doi: 10.1182/asheducation-2017.1.470. Review. PubMed PMID: 29222295.

Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. **Blood**. 2017 Dec 7;130(23):2475-2483. doi: 10.1182/blood-2017-06-782037. Review. PubMed PMID: 29212804.

Newman R, Ahlfors H, Saveliev A, Galloway A, Hodson DJ, Williams R, Besra GS, Cook CN, Cunningham AF, Bell SE, Turner M. Maintenance of the marginal-zone B cell compartment specifically requires the RNA-binding protein ZFP36L1. **Nat Immunol**. 2017 Jun;18(6):683-693. doi: 10.1038/ni.3724. Epub 2017 Apr 10. PubMed PMID: 28394372; PubMed Central PMCID: PMC5438597.

Pratt G, Yap C, Oldreive C, Slade D, Bishop R, Griffiths M, Dyer MJS, Fegan C, Oscier D, Pettitt A, Matutes E, Devereux S, Allsup D, Bloor A, Hillmen P, Follows G, Rule S, Moss P, Stankovic T. A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. **Br J Haematol**. 2017 Jun 23. doi: 10.1111/bjh.14793. [Epub ahead of print] PubMed PMID: 28643365.

Rosenquist R, Beà S, Du MQ, Nadel B, Pan-Hammarström Q. Genetic landscape and deregulated pathways in B-cell lymphoid malignancies. **J Intern Med**. 2017 Nov;282(5):371-394. doi: 10.1111/joim.12633. Epub 2017 Jun 20. Review. PubMed PMID: 28631441

Snowden JA, O'Connell S, Hawkins J, Dalley C, Jack A, Mannari D, McNamara C, Scott M, Shenton G, Soilleux E, Macbeth F; Guideline Committee. Haematological cancers: improving outcomes. A summary of updated NICE service guidance in relation to Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS). **J Clin Pathol**. 2017 Jun;70(6):461-468. doi: 10.1136/jclinpath-2016-204029. Epub 2017 Apr 7. Review. PubMed PMID: 28389440.

Till KJ, Allen JC, Talab F, Lin K, Allsup D, Cawkwell L, Bentley A, Ringshausen I, Duckworth AD, Pettitt AR, Kalakonda N, Slupsky JR. Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. **Sci Rep**. 2017 Dec 1;7(1):16784. doi:10.1038/s41598-017-17021-w. PubMed PMID: 29196709; PubMed Central PMCID: PMC5711840.

Tucker DL, Naylor G, Kruger A, Hamilton MS, Follows G, Rule SA. Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom. **Br J Haematol**. 2017 Jul;178(2):327-329. doi: 10.1111/bjh.14122. Epub 2016 May 16. PubMed PMID: 27197509.

Varghese AM, Howard DR, Pocock C, Rawstron AC, Follows G, McCarthy H, Dearden C, Fegan C, Milligan D, Smith AF, Gregory W, Hillmen P; NCRI CLL Sub-Group. Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. **Br J Haematol**. 2017 Feb;176(4):573-582. doi: 10.1111/bjh.14342. Epub 2016 Dec 29. PubMed PMID: 28032335.

Wang M, Zhang S, Chuang SS, Ashton-Key M, Ochoa E, Bolli N, Vassiliou G, Gao Z, Du MQ. Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling. **Oncotarget**. 2017 Mar 14;8(11):17763-17770. doi: 10.18632/oncotarget.14846. PubMed PMID: 28148900; PubMed Central PMCID: PMC5392284.

## 2016

Barrett NA, Malouf C, Kapeni C, Bacon WA, Giotoopoulos G, Jacobsen SEW, Huntly BJ, Ottersbach K. Mll-AF4 Confers Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development. **Cell Rep**. 2016 Jul 26;16(4):1039-

1054. doi: 10.1016/j.celrep.2016.06.046. Epub 2016 Jul 7. PubMed PMID: 27396339; PubMed Central PMCID: PMC4967476.

Bolli N, Li Y, Sathiaselvan V, Raine K, Jones D, Ganly P, Cocito F, Bignell G, Chapman MA, Sperling AS, Anderson KC, Avet-Loiseau H, Minvielle S, Campbell PJ, Munshi NC. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. **Blood Cancer J**. 2016 Sep 2;6(9):e467. doi: 10.1038/bcj.2016.72. PubMed PMID: 27588520; PubMed Central PMCID: PMC5056967.

Ceccon M, Merlo MEB, Mologni L, Poggio T, Varesio LM, Menotti M, Bombelli S, Rigolio R, Manazza AD, Di Giacomo F, Ambrogio C, Giudici G, Casati C, Mastini C, Compagno M, Turner SD, Gambacorti-Passerini C, Chiarle R, Voena C. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. **Oncogene**. 2016 Jul 21;35(29):3854-3865. doi: 10.1038/onc.2015.456. Epub 2015 Dec 14. PubMed PMID: 26657151; PubMed Central PMCID: PMC4907875.

Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner CM, Follows GA, Hüllein J, Jethwa A, Ellert E, Walther T, Liu X, Dyer MJ, Elter T, Brummer T, Zeiser R, Hermann M, Herold M, Weichert W, Dearden C, Haferlach T, Seiffert M, Hallek M, von Kalle C, Ho AD, Gaehler A, Andrusis M, Steurer M, Zenz T. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. **Blood**. 2016 Jun 9;127(23):2847-55. doi: 10.1182/blood-2015-11-680074. Epub 2016 Mar 3. PubMed PMID: 26941398.

Du MQ. MALT lymphoma: A paradigm of NF- $\kappa$ B dysregulation. **Semin Cancer Biol**. 2016 Aug;39:49-60. doi: 10.1016/j.semcancer.2016.07.003. Epub 2016 Jul 21. Review. PubMed PMID: 27452667.

Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research. The European Hematology Association Roadmap for European Hematology Research: a consensus document. **Haematologica**. 2016 Feb;101(2):115-208. doi: 10.3324/haematol.2015.136739. Epub 2016 Jan 27. PubMed PMID: 26819058; PubMed Central PMCID: PMC4938336.

Escudero-Ibarz L, Wang M, Du MQ. Significant functional difference between TNFAIP3 truncation and missense mutants. **Haematologica**. 2016 Sep;101(9):e382-4. doi: 10.3324/haematol.2016.148346. Epub 2016 Jun 13. PubMed PMID: 27479826; PubMed Central PMCID: PMC5060036.

Eyre TA, Clifford R, Bloor A, Boyle L, Roberts C, Cabes M, Collins GP, Devereux S, Follows G, Fox CP, Gribben J, Hillmen P, Hatton CS, Littlewood TJ, McCarthy H, Murray J, Pettitt AR, Soilleux E, Stamatopoulos B, Love SB, Wotherspoon A, Schuh A. NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. **Br J Haematol**. 2016 Oct;175(1):43-54. doi: 10.1111/bjh.14177. Epub 2016 Jul 5. PubMed PMID: 27378086.

Galloway A, Saveliev A, Łukasiak S, Hodson DJ, Bolland D, Balmanno K, Ahlfors H, Monzón-Casanova E, Mannurita SC, Bell LS, Andrews S, Díaz-Muñoz MD, Cook SJ, Corcoran A, Turner M. RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence. **Science**. 2016 Apr 22;352(6284):453-9. doi: 10.1126/science.aad5978. PubMed PMID: 27102483.

Giotopoulos G, Chan WI, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E, Campbell PJ, Göttgens B, Van Deursen JM, Cole PA, Huntly BJ. The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. **Oncogene**. 2016 Jan 21;35(3):279-89. doi: 10.1038/onc.2015.92. Epub 2015 Apr 20. PubMed PMID: 25893291; PubMed Central PMCID: PMC4729186.

Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. **Blood**. 2016 Jan 7;127(1):29-41. doi: 10.1182/blood-2015-07-604496. Epub 2015 Dec 10. Review. PubMed PMID: 26660431; PubMed Central PMCID: PMC4705608.

Hassler MR, Pulverer W, Lakshminarasimhan R, Redl E, Hacker J, Garland GD, Malcolm TI, Hodson DJ, Macintyre EA, Turner SD. Challenging perspectives on the cellular origins of lymphoma. **Open Biol**. 2016 Sep;6(9). pii: 160232. PubMed PMID: 27683157; PubMed Central PMCID: PMC5043587.

Hodson DJ, Shaffer AL, Xiao W, Wright GW, Schmitz R, Phelan JD, Yang Y, Webster DE, Rui L, Kohlhammer H, Nakagawa M, Waldmann TA, Staudt LM. Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2. **Proc Natl Acad Sci U S A**. 2016 Apr 5;113(14):E2039-46. doi: 10.1073/pnas.1600557113. Epub 2016 Mar 18. PubMed PMID: 26993806; PubMed Central PMCID: PMC4833274.

Lacombe F, Bernal E, Bloxham D, Couzens S, Porta MG, Johansson U, Kern W, Macey M, Matthes T, Morilla R, Paiva A, Palacio C, Preijers F, Ratei R, Siitonen S, Allou K, Porwit A, Béné MC. Harmonemia: a universal strategy for flow cytometry immunophenotyping-A European LeukemiaNet WP10 study. **Leukemia**. 2016 Aug;30(8):1769-72. doi: 10.1038/leu.2016.44. Epub 2016 Feb 29. PubMed PMID: 26922887.

Malcolm TI, Villarese P, Fairbairn CJ, Lamant L, Trinquand A, Hook CE, Burke GA, Brugières L, Hughes K, Payet D, Merkel O, Schiefer AI, Ashankyty I, Mian S, Wasik M, Turner M, Kenner L, Asnafi V, Macintyre E, Turner SD. Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. **Nat Commun**. 2016 Jan 12;7:10087. doi: 10.1038/ncomms10087. PubMed PMID: 26753883; PubMed Central PMCID: PMC4729925.

Mascarenhas MI, Bacon WA, Kapeni C, Fitch SR, Kimber G, Cheng SW, Li J, Green AR, Ottersbach K. Analysis of Jak2 signaling reveals resistance of mouse embryonic hematopoietic stem cells to myeloproliferative disease mutation. **Blood**. 2016 May 12;127(19):2298-309. doi: 10.1182/blood-2015-08-664631. Epub 2016 Feb 10. PubMed PMID: 26864339; PubMed Central PMCID: PMC4882783.

McKerrell T, Moreno T, Ponstingl H, Bolli N, Dias JM, Tischler G, Colonna V, Manasse B, Bench A, Bloxham D, Herman B, Fletcher D, Park N, Quail MA, Manes N, Hodgkinson C, Baxter J, Sierra J, Foukaneli T, Warren AJ, Chi J, Costeas P, Rad R, Huntly B, Grove C, Ning Z, Tyler-Smith C, Varela I, Scott M, Nomdedeu J, Merkel O, Schiefer AI, Simonitsch-Klupp I, Kenner L, Weisenberger DJ, Weinhaeusel A, Turner SD, Egger G. Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling. **Cell Rep**. 2016 Oct 4;17(2):596-608. doi: 10.1016/j.celrep.2016.09.018. PubMed PMID: 27705804.

Mustonen V, Vassiliou GS. Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. **Blood**. 2016 Jul 7;128(1):e1-9. doi:10.1182/blood-2015-11-683334. Epub 2016 Apr 27. PubMed PMID: 27121471; PubMed Central PMCID: PMC4937362.

Nangalia J, Grinfeld J, Green AR. Pathogenesis of Myeloproliferative Disorders. **Annu Rev Pathol**. 2016 May 23;11:101-26. doi: 10.1146/annurev-pathol-012615-044454. Review. PubMed PMID: 27193452.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Seraihi AF, Richter J, Bernhart SH, Efeyan A, Iqbal S, Matthews J, Clear A, Guerra-Assunção JA, Bödör C, Quentmeier H, Mansbridge C, Johnson P, Davies A, Strefford JC, Packham G, Barrans S, Jack A, Du MQ, Calaminici M, Lister TA, Auer R, Montoto S, Gribben JG, Siebert R, Chelala C, Zoncu R, Sabatini DM, Fitzgibbon J. Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. **Nat Genet**. 2016 May 27;48(6):700. doi: 10.1038/ng0616-700b. PubMed PMID: 27230687.

Park HJ, Li J, Hannah R, Biddie S, Leal-Cervantes AI, Kirschner K, Flores Santa Cruz D, Sexl V, Göttgens B, Green AR. Cytokine-induced megakaryocytic differentiation is regulated by genome-wide loss of a uSTAT transcriptional program. **EMBO J**. 2016 Mar 15;35(6):580-94. doi: 10.15252/embj.201592383. Epub 2015 Dec 23. PubMed PMID: 26702099; PubMed Central PMCID: PMC4801948.

Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du MQ, Akasaka T, Parker A, Roa S, Panizo C, Martin-Guerrero I, Siebert R, Segura V, Agirre X, Macri-Pellizeri L, Aldaz B, Vilas-Zornoza A, Zhang S, Moody S, Calasanz MJ, Tousseyn T, Broccardo C, Brousset P, Campos-Sanchez E, Cobaleda C, Sanchez-Garcia I, Fernandez-Luna JL, Garcia-Muñoz R, Pena E, Bellosillo B, Salar A, Baptista MJ, Hernandez-Rivas JM, Gonzalez M, Terol MJ, Climent J, Ferrandez A, Sagaert X, Melnick AM, Prosper F, Oscier DG, Carrasco YR, Dyer MJ, Martinez-Climent JA. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. **Nat Commun**. 2016 Jun 14;7:11889. doi: 10.1038/ncomms11889. PubMed PMID: 27297662; PubMed Central PMCID: PMC4911677.

Rosenquist R, Rosenwald A, Du MQ, Gaidano G, Groenen P, Wotherspoon A, Ghia P, Gaulard P, Campo E, Stamatopoulos K; European Research Initiative on CLL (ERIC) and the European Association for Haematopathology (EAHP). Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond.

**Haematologica**. 2016 Sep;101(9):1002-9. doi: 10.3324/haematol.2015.134510. Review. PubMed PMID: 27582569; PubMed Central PMCID: PMC5060016

Rui L, Drennan AC, Ceribelli M, Zhu F, Wright GW, Huang DW, Xiao W, Li Y, Grindle KM, Lu L, Hodson DJ, Shaffer AL, Zhao H, Xu W, Yang Y, Staudt LM. Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. **Proc Natl Acad Sci U S A**. 2016 Nov 15;113(46):E7260-E7267. Epub 2016 Oct 31. PubMed PMID: 27799566; PubMed Central PMCID: PMC5135360.

Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. **Haematologica**. 2016 Feb;101(2):235-40. doi: 10.3324/haematol.2015.128710. Epub 2015 Nov 26. PubMed PMID: 26611473; PubMed Central PMCID: PMC4938327.

Sasca D, Huntly BJ. Independence of epigenetic and genetic diversity in AML. **Nat Med**. 2016 Jul 7;22(7):708-9. doi: 10.1038/nm.4136. PubMed PMID: 27387883.

Sciacovelli M, Gonçalves E, Johnson TI, Zecchini VR, da Costa AS, Gaude E, Drubbel AV, Theobald SJ, Abbo SR, Tran MG, Rajeeve V, Cardaci S, Foster S, Yun H, Cutillas P, Warren A, Gnanapragasam V, Gottlieb E, Franze K, Huntly B, Maher ER, Maxwell PH, Saez-Rodriguez J, Frezza C. Corrigendum: Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. **Nature**. 2016 Dec 1;540(7631):150. doi: 10.1038/nature20144. Epub 2016 Oct 19. PubMed PMID: 27760119.

Speedy HE, Kinnersley B, Chubb D, Broderick P, Law PJ, Litchfield K, Jayne S, Dyer MJS, Dearden C, Follows GA, Catovsky D, Houlston RS. Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia. **Blood**. 2016 Nov 10;128(19):2319-2326. doi: 10.1182/blood-2016-01-695692. Epub 2016 Aug 15. PubMed PMID: 27528712; PubMed Central PMCID: PMC5271173.

Turner SD, Lamant L, Kenner L, Brugières L. Anaplastic large cell lymphoma in paediatric and young adult patients. **Br J Haematol**. 2016 May;173(4):560-72. doi: 10.1111/bjh.13958. Epub 2016 Feb 23. Review. PubMed PMID: 26913827.

Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo, A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJP, Iorio F, Pina C, Vassiliou GS, Yusa K. A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. **Cell Rep**. 2016 Oct 18;17(4):1193-1205. doi: 10.1016/j.celrep.2016.09.079. PubMed PMID: 27760321; PubMed Central PMCID: PMC5081405.

Wagner M, Oelsner M, Moore A, Götte F, Kuhn PH, Haferlach T, Fiegl M, Bogner C, Baxter EJ, Peschel C, Follows GA, Ringshausen I. Integration of innate into

adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia. **Blood**. 2016 Jan 28;127(4):436-48. doi: 10.1182/blood-2015-05-646935. Epub 2015 Oct 27. PubMed PMID: 26508782.

Yeung J, Tourdot BE, Adili R, Green AR, Freedman CJ, Fernandez-Perez P, Yu J, Holman TR, Holinstat M. 12(S)-HETrE, a 12-Lipoxygenase Oxylin of Dihomo- $\gamma$ -Linolenic Acid, Inhibits Thrombosis via Gas Signaling in Platelets. **Arterioscler Thromb Vasc Biol**. 2016 Oct;36(10):2068-77. doi: 10.1161/ATVBAHA.116.308050. Epub 2016 Jul 28. PubMed PMID: 27470510; PubMed Central PMCID: PMC5488693.

## 2015

Basheer F, Huntly BJ. BET bromodomain inhibitors in leukemia. **Exp Hematol**. 2015 Aug;43(8):718-31. doi: 10.1016/j.exphem.2015.06.004. Epub 2015 Jul 9. Review. PubMed PMID: 26163798.

Chen E, Ahn JS, Sykes DB, Breyfogle LJ, Godfrey AL, Nangalia J, Ko A, DeAngelo DJ, Green AR, Mullally A. RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. **Cell Rep**. 2015 Dec 22;13(11):2345-2352. doi: 10.1016/j.celrep.2015.11.037. Epub 2015 Dec 10. PubMed PMID: 26686625; PubMed Central PMCID: PMC4691544.

Clipson A, Barrans S, Zeng N, Crouch S, Grigoropoulos NF, Liu H, Kocialkowski S, Wang M, Huang Y, Worrillow L, Goodlad J, Buxton J, Neat M, Fields P, Wilkins B, Grant JW, Wright P, Ei-Daly H, Follows GA, Roman E, Watkins AJ, Johnson PW, Jack A, Du MQ. The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit. **J Pathol Clin Res**. 2015 Mar 30;1(3):125-133. eCollection 2015 Jul. PubMed PMID: 27347428; PubMed Central PMCID: PMC4915334.

Clipson A, Wang M, de Leval L, Ashton-Key M, Wotherspoon A, Vassiliou G, Bolli N, Grove C, Moody S, Escudero-Ibarz L, Gundem G, Brugger K, Xue X, Mi E, Bench A, Scott M, Liu H, Follows G, Robles EF, Martinez-Climent JA, Oscier D, Watkins AJ, Du MQ. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. **Leukemia**. 2015 May;29(5):1177-85. doi: 10.1038/leu.2014.330. Epub 2014 Nov 27. PubMed PMID: 25428260.

Follows GA. Balancing Risks in Developing a Personalised Approach to the Treatment of Early Hodgkin Lymphoma: A Haematologist's Perspective. **Clin Oncol (R Coll Radiol)**. 2015 Aug;27(8):457-9. doi: 10.1016/j.clon.2015.05.008. Epub 2015 Jun 10. PubMed PMID: 26071896.

Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S, Tyler D, Stanley K, Sinha D, Yeh P, Morison J, Giotopoulos G, Lugo D, Jeffrey P, Lee SC, Carpenter C, Gregory R, Ramsay RG, Lane SW, Abdel-Wahab O, Kouzarides T, Johnstone RW, Dawson SJ, Huntly BJ, Prinjha RK, Papenfuss AT, Dawson MA. BET inhibitor resistance emerges from leukaemia stem cells. **Nature**. 2015 Sep 24;525(7570):538-42. doi: 10.1038/nature14888. Epub 2015 Sep 14. PubMed PMID: 26367796.

Gallipoli P, Giotopoulos G, Huntly BJ. Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. **Ther Adv Hematol**. 2015 Jun;6(3):103-19. doi: 10.1177/2040620715577614. Review. PubMed PMID: 26137202; PubMed Central PMCID: PMC4480521.

Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan WI, Foster D, Prinjha RK, Pimanda JE, Tenen DG, Vassiliou GS, Koschmieder S, Adams DJ, Huntly BJ. A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. **J Exp Med**. 2015 Sep 21;212(10):1551-69. doi: 10.1084/jem.20141661. Epub 2015 Aug 24. PubMed PMID: 26304963; PubMed Central PMCID: PMC4577832.

Giuriato S, Turner SD. Twenty years of modelling NPM-ALK-induced lymphomagenesis. **Front Biosci (Schol Ed)**. 2015 Jun 1;7:236-47. Review. PubMed PMID: 25961699.

Jhuang JY, Clipson A, Hsieh YC, Yang CC, Chang ST, Du MQ, Chuang SS. Aggressive natural killer-cell neoplasm presenting in the marrow: a report of two cases including one with gains of chromosomes 4q and 9p. **Diagn Pathol**. 2015 Jul 4;10:88. doi: 10.1186/s13000-015-0333-x. PubMed PMID: 26141723; PubMed Central PMCID: PMC4491245.

Merkel O, Kenner L, Turner SD. Stem cell hunt in NHL. **Oncoscience**. 2015 Sep 3;2(10):809-10. eCollection 2015. PubMed PMID: 26682256; PubMed Central PMCID:PMC4671931.

Merkel O, Hamacher F, Griessl R, Grabner L, Schiefer AI, Prutsch N, Baer C, Egger G, Schleder M, Krenn PW, Hartmann TN, Simonitsch-Klupp I, Plass C, Staber PB, Moriggl R, Turner SD, Greil R, Kenner L. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. **J Pathol**. 2015 Aug;236(4):445-56. doi: 10.1002/path.4539. Epub 2015 Apr 27. PubMed PMID: 25820993; PubMed Central PMCID: PMC4557053.

Mifsud B, Tavares-Cadete F, Young AN, Sugar R, Schoenfelder S, Ferreira L, Wingett SW, Andrews S, Grey W, Ewels PA, Herman B, Happe S, Higgs A, LeProust E, Follows GA, Fraser P, Luscombe NM, Osborne CS. Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. **Nat Genet**. 2015 Jun;47(6):598-606. doi: 10.1038/ng.3286. Epub 2015 May 4. PubMed PMID: 25938943.

Moti N, Malcolm T, Hamoudi R, Mian S, Garland G, Hook CE, Burke GA, Wasik MA, Merkel O, Kenner L, Laurenti E, Dick JE, Turner SD. Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin. **Oncogene**. 2015 Apr 2;34(14):1843-52. doi: 10.1038/onc.2014.112. Epub 2014 May 12. PubMed PMID: 24814516.

Nie Z, Du MQ, McAllister-Lucas LM, Lucas PC, Bailey NG, Hogaboam CM, Lim MS, Elenitoba-Johnson KS. Conversion of the LIMA1 tumour suppressor into an

oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma. **Nat Commun.** 2015 Jan 8;6:5908. doi: 10.1038/ncomms6908. PubMed PMID: 25569716.

van der Weyden L, Giotopoulos G, Wong K, Rust AG, Robles-Espinoza CD, Osaki H, Huntly BJ, Adams DJ. Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia. **BMC Cancer.** 2015 Aug 13;15:585. doi:10.1186/s12885-015-1586-1. PubMed PMID: 26269126; PubMed Central PMCID: PMC4542115.

Wang M, Escudero-Ibarz L, Moody S, Zeng N, Clipson A, Huang Y, Xue X, Grigoropoulos NF, Barrans S, Worrillow L, Forshew T, Su J, Firth A, Martin H, Jack A, Brugger K, Du MQ. Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina Sequencing. **J Mol Diagn.** 2015 Sep;17(5):521-32. doi: 10.1016/j.jmoldx.2015.04.008. Epub 2015 Jul 9. PubMed PMID: 26165823; PubMed Central PMCID: PMC4597275

Xue X, Zeng N, Gao Z, Du MQ. Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR. **Lab Invest.** 2015 Jan;95(1):113-20. doi: 10.1038/labinvest.2014.136. Epub 2014 Nov 24. PubMed PMID: 25418578.